KLOW Peptide Blend: Ingredients, Evidence, and Risks

Q: What is in the KLOW peptide blend?

KLOW usually contains GHK-Cu, BPC-157, TB-500, and KPV. Product ratios can differ. The product label and pharmacy record are the only reliable sources for the contents of a specific vial.

Q: Has KLOW been tested in a human clinical trial?

No controlled human trial has tested the complete four-ingredient KLOW blend. Studies of one ingredient cannot establish the safety or effectiveness of the combination.

Q: Is KLOW FDA-approved?

No. KLOW is not an FDA-approved drug. FDA is separately reviewing some of its ingredients for possible inclusion on the 503A Bulks List, but that process is not drug approval.

Q: Is TB-500 the same as thymosin beta-4?

The names are often used as if they mean the same product, but this can be inaccurate. Published human wound studies used full thymosin beta-4. A seller can use the name TB-500 for a related or shorter peptide product. The identity must be confirmed from the product record and laboratory report.

Q: Does adding four peptides make KLOW more effective?

There is no clinical evidence that the four ingredients work better together. A fixed ratio can also prevent a clinician from changing one ingredient without changing all four.

Key takeaways

KLOW is a fixed-ratio blend of GHK-Cu, BPC-157, TB-500, and KPV. It is not one new peptide.
No controlled human trial has tested the complete KLOW blend for recovery, inflammation, skin changes, or any other outcome.
Evidence for one ingredient does not prove that the four-ingredient blend is effective or safe.
FDA is reviewing BPC-157, KPV, and TB-500 for possible use in pharmacy compounding. An advisory review is not an approval.

KLOW is a marketed blend of four substances: GHK-Cu, BPC-157, TB-500, and KPV. The name suggests one product. The evidence does not support that simple view.

Researchers have studied the ingredients separately. They have used different routes, formulations, and disease models. No controlled human trial has tested the complete KLOW blend. This fact must guide every claim about the product.

This article explains the evidence. It does not give injection, mixing, or dose instructions.

What is KLOW?

KLOW usually contains:

Ingredient	Main reason it appears in the blend	Best available evidence
GHK-Cu	Skin repair and collagen claims	Cell studies, animal studies, and small topical human studies
BPC-157	Tissue and gastrointestinal repair claims	Mostly animal studies; very small human pilot studies
TB-500	Cell movement and wound repair claims	Human studies exist for full thymosin beta-4, but product identity is a key problem
KPV	Anti-inflammatory claims	Cell and animal studies, including mouse colitis models

The blend has a basic evidence problem. Four separate research files do not become one clinical trial when manufacturers put the ingredients in one vial.

What the evidence says about each ingredient

GHK-Cu

GHK-Cu is a copper-binding tripeptide. Laboratory studies show effects on fibroblasts and components of the extracellular matrix. A human fibroblast study found increased synthesis of some glycosaminoglycans. This result supports a biological mechanism. It does not prove systemic recovery benefits.

Small topical studies give limited human evidence. In a randomized study after carbon-dioxide laser treatment, 13 patients completed the trial. Objective assessments did not find significant improvement in redness, wrinkles, or overall skin quality between groups. Patient satisfaction was higher in the GHK-Cu group.

These results apply to topical skin products. They do not prove that injected GHK-Cu has the same effect.

BPC-157

BPC-157 has a large preclinical literature. Most studies use cells, rats, or other laboratory models. Human data remain small.

A 2024 pilot study treated 12 women who had interstitial cystitis. The study had no placebo group and used a local bladder procedure. It cannot prove that injected BPC-157 improves general recovery, tendons, or joints.

FDA's 2026 BPC-157 briefing document reviews the substance for possible pharmacy compounding. This is a regulatory review. It is not proof of safety, effectiveness, or approval.

TB-500

TB-500 creates a naming problem. Many pages connect it to thymosin beta-4. Published human research has mainly tested full thymosin beta-4, including topical products for wounds.

A 73-person Phase 2 study tested topical thymosin beta-4 for venous ulcers. The safety results were similar to placebo, and one dose showed a possible healing signal. This study did not test a KLOW injection. It also does not prove that every product sold as TB-500 contains the same molecule used in the study.

FDA published a separate 2026 TB-500 briefing document. The document evaluates TB-500-related bulk substances for compounding. It does not approve a commercial KLOW blend.

KPV

KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone. Researchers study it for inflammatory effects.

In a 2008 Gastroenterology study, KPV reduced inflammatory signaling in cultured cells and reduced inflammation in two mouse colitis models. Another rabbit study reported faster corneal surface healing after topical KPV.

These are not controlled human treatment trials. They do not show that KPV improves whole-body inflammation when it is part of KLOW.

FDA's 2026 KPV briefing document notes that KPV is promoted in combinations with BPC-157 and TB-500. The agency is evaluating the bulk substance. This does not validate the combination.

Why the fixed ratio matters

A fixed-ratio blend connects four separate decisions. If a prescriber changes the amount of one ingredient, the amounts of the other three also change.

This creates three problems:

A side effect is harder to connect to one ingredient.
A product-quality problem can affect the complete blend.
A person cannot stop one ingredient while continuing the others from the same vial.

The blend can also contain peptide-related impurities or aggregates. FDA lists injectable GHK-Cu as a substance that can present significant safety risks in compounding. FDA cites limited human safety information and possible immune reactions from aggregates or impurities.

Is KLOW FDA-approved?

No. FDA has not approved KLOW as a drug.

On July 23, 2026, an FDA advisory committee is scheduled to discuss BPC-157, KPV, and TB-500-related substances for possible inclusion on the 503A Bulks List. The official meeting page states that advisory recommendations are not binding.

The 503A process and the drug-approval process are different. Possible permission for a pharmacy to use a bulk substance does not show that the substance treats a disease. It also does not approve the KLOW combination.

How to assess a KLOW claim

Use four checks:

Ask whether the source studied the full blend or only one ingredient.
Check whether the study used humans, animals, or cells.
Check whether the route was topical, oral, local, or systemic.
Confirm whether TB-500 means the same molecule as the thymosin beta-4 study.

If a claim does not answer these questions, it is not complete.

Bottom line

KLOW combines four active research substances, but the blend has no direct clinical evidence. GHK-Cu has limited topical human data. Full thymosin beta-4 has some human wound data. BPC-157 has very small pilot studies. KPV has mainly cell and animal data.

This evidence can support more research. It cannot support a claim that KLOW is a proven recovery, skin, gut, or anti-inflammatory treatment.

Sources

Educational information only. KLOW and its research-peptide ingredients are not FDA-approved treatments. This article does not recommend use or provide medical instructions.